Persistent clinical benefit was seen among a small group of patients with metastatic renal cell carcinoma who had to discontinue therapy with the PD-1 inhibitor nivolumab (Opdivo) because of immune-related adverse events, according to a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Administration of broad-spectrum antibiotics in patients with metastatic renal cell carcinoma (RCC) undergoing treatment with immune checkpoint inhibitors may have a negative effect on the efficacy of the immunotherapy drugs, according to the results of a recent retrospective analysis.
Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
A recent study of patients with a new diagnosis of microhematuria finds that rates of bladder and kidney cancer as well as urolithiasis depend on how thoroughly the patients are evaluated.
Results from a recent prospective trial suggest that active surveillance may be suitable for some patients with advanced renal cell carcinoma.
Once-daily treatment with cabozantinib (CABOMETYX), an oral tyrosine kinase inhibitor, significantly improves overall survival as well as progression-free survival and objective responses rates compared with everolimus (Afinitor) in previously treated patients with advanced renal cell carcinoma, according to final results from the phase III METEOR trial.
Other products discussed in this roundup include a smart-mobile connected ultrasound device, treatments for RCC, and more.
FDA approval of second-line therapies could mean an “embarrassment of riches” in this field, according to one expert.
The procedure maximally preserves normal renal parenchyma and provides better surgical precision than standard partial nephrectomy, researchers report.
To guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.
In a head-to-head comparison, sunitinib (Sutent) prolonged radiographic progression-free survival compared with everolimus (Afinitor), but with greater toxicity, in patients with specific subtypes of metastatic renal cell carcinoma and non-clear cell histology, said Andrew J. Armstrong, MD, MSc.
Check out the latest new products. From Single-use ureteroscope addresses shortcomings of reusable scopes, to an App that helps IC, chronic prostatitis patients choose the right foods and much more.
In this interview, E. Jason Abel, MD, discusses biopsy’s role in small and large renal masses, associated risks, and when patients can be safely observed.
Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.
In this interview Mark A. Preston, MD, MPH, of Brigham and Women’s hospital sat down with Richard. R. Kerr, Urology Times content channel director, to discuss the association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts. The interview was conducted during the AUA annual meeting in New Orleans.
A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.
Study findings point to “a concept that has haunted clinical trialists for years,” says one expert.
An immune checkpoint inhibitor provides “a real opportunity to change clinical practice” for patients with metastatic renal cell carcinoma, a study author says.
In this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.
The survival benefit associated with high-dose IL-2 in metastatic renal cell carcinoma may be better than previously believed.
Two angiogenesis inhibitors that are widely used in metastatic renal cell carcinoma did not improve survival compared with placebo when used as adjuvant treatment, a new study found.
A novel optical imaging technology is showing promise as a potential diagnostic tool for renal cell carcinoma.
New, large-scale studies on active surveillance, IMRT complications, and robotic versus open prostatectomy were among the highlights of this year’s Genitourinary Cancers Symposium.
Kidney cancer patients were more likely to undergo partial nephrectomy when treated in hospitals that were early adopters of robotic surgery, according to a recent report that one leading expert calls “some of the best evidence to date of a favorable impact of surgical robots in urologic care.”
Monish Aron, MD, presents the take home messages on kidney cancer from the AUA annual meeting in Orlando, FL.
